Miller K - Search Results

1

Evidence for benefits and risks of tadalafil as a non-prescription medicine: review and evaluation using the Group Delphi technique to achieve consensus amongst clinical experts.

Miller K, May U, Beecken WD, Hatzichristodoulou G, Böhm M, Fink S. Miller K, et al. Front Pharmacol. 2023 Oct 9;14:1254706. doi: 10.3389/fphar.2023.1254706. eCollection 2023. Front Pharmacol. 2023. PMID: 37876727 Free PMC article.

2

T1G3 bladder cancer--the case for TUR and BCG.

Miller K. Miller K. Front Radiat Ther Oncol. 2002;36:147-50. doi: 10.1159/000061336. Front Radiat Ther Oncol. 2002. PMID: 11842744 Review. No abstract available.

3

Urolithiasis in Renal Allografts: Complications and Outcomes.

Friedersdorff F, El-Bandar N, Busch J, Erber B, Miller K, Fuller TF, Miller K. Friedersdorff F, et al. Among authors: miller k. Exp Clin Transplant. 2017 Apr;15(2):164-170. doi: 10.6002/ect.2016.0040. Epub 2016 Nov 18. Exp Clin Transplant. 2017. PMID: 27855586 Free article.

4

[And what is in the works now? Recent developments in therapy of prostate cancer (interview by Constanze Loffler)].

Miller K. Miller K. MMW Fortschr Med. 2009 Jul 23;151(30-33):72-3. MMW Fortschr Med. 2009. PMID: 19722471 German. No abstract available.

5

[Management of metastatic hormone-sensitive prostate cancer - Current treatment options, criteria for progression and switch of therapy].

Miller K. Miller K. Aktuelle Urol. 2023 May 26. doi: 10.1055/a-2055-0869. Online ahead of print. Aktuelle Urol. 2023. PMID: 37236233 German.

6

[Management of metastatic hormone-sensitive prostate cancer - Current treatment options, criteria for progression and switch of therapy].

Miller K Prof. Miller K Prof. Aktuelle Urol. 2023 Jul 14. doi: 10.1055/a-2110-9321. Online ahead of print. Aktuelle Urol. 2023. PMID: 37451278 German. No abstract available.

7

[Interdisciplinary recommendations concerning the therapy for hormone-refractory prostatic carcinoma].

Miller K, Becker K, Finke F, Geiges G, Göckel-Beining B, Hossfeld DK, Miller K, Osieka R, Rüssel C, Tesch H, Weissbach L, Wirth M, Wolff JM. Miller K, et al. Aktuelle Urol. 2006 May;37(3):201-4. doi: 10.1055/s-2006-932205. Aktuelle Urol. 2006. PMID: 16733822 German.

8

Words of wisdom. Re: Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Scher HI, Beer TM, Higano CS, et al. Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium.

Miller K. Miller K. Eur Urol. 2010 Sep;58(3):464-5. doi: 10.1016/j.eururo.2010.06.018. Eur Urol. 2010. PMID: 20845529 No abstract available.

9

Words of wisdom. Re: PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. Whitman EJ, Groskopf J, Ali A, et al. J Urol 2008;180:1975-8; discussion 1978-9.

Miller K. Miller K. Eur Urol. 2009 Jul;56(1):218-9. doi: 10.1016/j.eururo.2009.04.015. Eur Urol. 2009. PMID: 19995518 No abstract available.

10

Human kidney 11 beta-hydroxysteroid dehydrogenase: regulation by adrenocorticotropin?

Diederich S, Quinkler M, Miller K, Heilmann P, Schoneshofer M, Oelkers W. Diederich S, et al. Among authors: miller k. Eur J Endocrinol. 1996 Mar;134(3):301-7. doi: 10.1530/eje.0.1340301. Eur J Endocrinol. 1996. PMID: 8616526

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

7,784 results

Search Page

Filters